| Project/Area Number |
15K19426
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Jichi Medical University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
Ushijima Kentaro 自治医科大学, 医学部, 講師 (70448843)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | mTOR阻害薬 / Temsirolimus / 肺傷害 / 糖尿病 / 血糖降下薬 / 2型糖尿病 / 間質性肺炎 / 間質性肺疾患 |
|---|
| Outline of Final Research Achievements |
mTOR inhibitors have recently been developed as antineoplastic targeted therapies in various cancers. However, mTOR inhibitors have several adverse effects, including interstitial lung disease and type 2 diabetes. We recently found that temsirolimus induced interstitial lung disease more frequently in patients with diabetes. It was the purpose of this experiment to reveal the association between temsirolimus-induced lung disease and type 2 diabetes. Male moderate diabetic mice or control mice were administered by temsirolimus or vehicle. A subgroup of diabetic mice administered with temsirolimus was treated by rosilgitazone maleate, glimepiride, or vehicle. Temsirolimus worsened type 2 diabetes markedly in diabetic mice. However, lung inflammation in diabetic mice was equivalent to that in control mice. Rosiglitazone ameliorated temsirolimus-induced type 2 diabetes but not lung inflammation. Glimepiride did not ameliorate temsirolimus-induced type 2 disbetes.
|
